Please login to the form below
systemic lupus erythematosus
This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.
Biogen doses first patient in phase 3 systemic lupus erythematosus study
Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... systemic and cutaneous lupus,” said Nathalie Franchimont, head of the multiple sclerosis and immunology
Latest news
-
Merck to acquire Pandion Therapeutics for $1.85bn
of systemic lupus erythematosus and ulcerative colitis. ... In addition, Amgen is testing its own IL-2 candidate – AMG-592 – in patients with systemic lupus erythematosus and chronic graft-versus-host disease.
-
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Elsewhere in its pipeline, Viela has a number of candidates in ongoing or planned phase 1/2 development – including VIB4920 for Sjögren’s syndrome, VIB7734 for systemic lupus erythematosus (SLE) and
-
Bayer signs €250m pact with India’s Curadev for STING drugs
in infancy (SAVI) and a subset of systemic lupus erythematosus (SLE).
-
Biogen scores mid-stage trial win for lupus drug BIIB059
Last approved treatment for Lupus was GSK's Benlysta in 2011. Biogen’s experimental drug for systemic lupus erythematosus (SLE) has hit the mark in a phase 2 trial, adding to ... BIIB059 hit all its objectives in the LILAC study, including a
-
Second TULIP trial resurrects AZ’s lupus drug anifrolumab
Will now decide whether to file treatment for approval. A year ago, prospects for AstraZeneca’s systemic lupus erythematosus treatment anifrolumab were being written off. ... Lupus is a disease in which the immune system attacks normal cells and tissues
Merck to acquire Pandion Therapeutics for $1.85bn
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Bayer signs €250m pact with India’s Curadev for STING drugs
Biogen scores mid-stage trial win for lupus drug BIIB059
Second TULIP trial resurrects AZ’s lupus drug anifrolumab
More from news
Approximately 2 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Rethinking trials: the pros and cons of protocol amendments
A protocol change can work wonders – just ask AstraZeneca. In August, AstraZeneca’s systemic lupus erythematosus candidate anifrolumab achieved the primary efficacy endpoint in an amended trial called Tulip-2. ... Systemic lupus erythematosus is a
-
Pharma deals during September 2012
In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus
Rethinking trials: the pros and cons of protocol amendments
Pharma deals during September 2012
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Santhera CEO Klaus Schollmeier joins SuppreMol
This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).
Santhera CEO Klaus Schollmeier joins SuppreMol
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Clinical trials and the diversity principle
Examples abound, but systemic lupus erythematosus (SLE) – a disease for which there has only been one new drug approval since 1955 – is a notable case in point: while Black people account ... COVID has been like a magnifying glass, revealing systemic
-
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
systemic lupus erythematosus (SLE).
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Biogen's ALS drug tofersen misses phase 3 endpoint
- What does HCP engagement look like in a post-Covid world?
- Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Valneva COVID-19 vaccine more effective than AZ
- Real-world data highlights flu vaccine efficacy
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
No results were found
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- What does HCP engagement look like in a post-Covid world?
- HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
